News

FDA Approves the First Infusion Therapy for Aggressive, Rare Blood Disease

01/21/2020

The FDA has approved tagraxofusp-erzs (Elzonris; Stemline Therapeutics) for the treatment of adults and children aged ≥2 years with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

The FDA has approved...

01/21/2020

Oncology

News

Experts Identify Factors for Poor Prognosis in Shwachman-Diamond Syndrome With MDS or AML

01/15/2020

Patients with Shwachman-Diamond syndrome and MDS or AML have a poor prognosis because of treatment-related toxicities.

Patients with Shwachman-Diamond...

01/15/2020

Oncology

News

Luspatercept Reduces Anemia Severity in Patients With MDS Receiving Transfusions

01/14/2020

Among patients with lower-risk MDS receiving regular red-cell transfusions, treatment with luspatercept reduces the severity of anemia.

Among patients with lower-risk...

01/14/2020

Oncology

News

Luspatercept Demonstrates Long-Term Safety and Efficacy for Anemia in Patients With MDS

12/27/2019

Long-term analyses of the MEDALIST study show sustained responses with durable clinical benefit in patients with MDS receiving luspatercept for anemia, superior to that of patients receiving placebo.

Long-term analyses of the...

12/27/2019

Oncology

News

Luspatercept Active in Patients with Myelofibrosis-Associated Anemia

12/27/2019

Initial results from an ongoing study suggest clinically significant activity of luspatercept for the treatment of myelofibrosis-associated anemia.

Initial results from an ongoing...

12/27/2019

Oncology

News

Ruxolitinib Plus Pomalidomide Feasible for Treatment of MF With Anemia

12/18/2019

Combining ruxolitinib therapy with pomalidomide is feasible for the treatment of patients with poor-risk MF and anemia, updated study findings show.

Combining ruxolitinib therapy...

12/18/2019

Oncology

News

Superior DFS and OS With FluMel vs FluBu in Older Patients With MDS

12/03/2019

A reduced-intensity conditioning regimen for older patients with MDS comprised of FluMel is tied to superior DFS and OS than FluBu according to data that will be presented at the 2019 ASH Annual Meeting.

A reduced-intensity conditioning...

12/03/2019

Oncology

News

NCCN Updates Guidelines for MDS

07/19/2018

The NCCN has published updates to their clinical practice guidelines for myelodysplastic syndromes, including updates to initial evaluation, additional testing, and prognostic categories.

The NCCN has published updates...

07/19/2018

Oncology

News

Alternative Therapy Superior to Standard Care in Patients With MF and Thrombocytopenia

03/13/2018

A JAK2/FLT3 inhibitor may be able to provide an alternative treatment option for patients with myelofibrosis and baseline thrombocytopenia.

A JAK2/FLT3 inhibitor may be...

03/13/2018

Oncology

News

Leukemic Transformation in MPNs a Major Challenge for Clinicians

02/20/2018

There is no standard of care treatment option for patients with leukemic transformation in myeloproliferative neoplasms, though new approaches may provide practice-changing strategies.

There is no standard of care...

02/20/2018

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology